How CA 125 is used in the routine follow-up of ovarian cancer: A survey of 29 Italian hospitals

Tumor Biology

Volumn 19, Issue 4, 1998, Pages 269-274

  Gion, Massimo ^a,d   Barioli, P ^a   Ponti, A ^b   Torri, V ^c   Mione, R ^a   Dittadi, R ^a  

^a Regional Hospital   (Italy)

^b Center for Epidemiology and Prevention in Oncology

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d ULSS   (Italy)

Author keywords

CA 125; Ovarian cancer; Tumor markers

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0031870939     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030017     Document Type: Article

References (14)

1. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio Sanitario Nazionale. Gazzetta Ufficiale n° 216 del 14/09/1996.
2. Eddy DM: What do we do about costs? Jama 1990;264:1161.
3. Liberati A: Valutazione del bisogno sanitario ed allocazione delle risorse: il difficile ruolo dell'epidemiologia; in Costa G, Faggiano F (eds): L'equità nella salute in Italia. Rapporte sulle diseguaglianze sociali in sanità. Milano, Angeli, 1994.
4. Borowitz M, Sheldom T: Controlling health care: From economic incentives to micro-clinical regulation. Health Econ 1993;2:201-205.
5. American Society of Clinical Oncology: Clinical Practice Guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-2877.
6. Canadian Task Force on the Periodic Health Examination: The periodic health examination. Can Med Assoc J 1979;121:1193-1254.
7. American Society of Clinical Oncology Outcomes Working Group: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1995;14:671-679.
8. Gion M, Rampazzo A, Mione R, Bruscagnin G: Cost/effectiveness ratio of carcinoembryonic antigen -Importance of adequacy of routine requests of tumor markers. Int J Biol Markers 1992;7:179-182.
9. Loprinzi CL, Ravdin PM, De Laurentiis M, Novotny P: Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? J Clin Oncol 1994;12:1422-1426.
10. Chassin MR, Brook RH, Park RE: Variations in the use of medical and surgical services by the Medicare population. N Engl J Med 1986;314:285-289.
11. Folland S, Stano M: Small area variations: A critical review of propositions, methods and evidence. Med Care Rev 1990;47:419-423.
12. Health Services Research Group: Small area variations: What are they and what do they mean? Can Med Assoc J 1992;146:467-470.
13. Hillner BE, Smith TJ: Methods of developing clinical practice guide-lines; in: American Society of Clinical Oncology Educational Book. Chicago, American Society of Clinical Oncology, 1994, pp 261-265.
14. Woolf SH: Practice guidelines: A new reality in medicine. Arch Intern Med 1990;150:1811-1816.